+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Polycystic Kidney Disease Drugs Market - Global Forecast 2025-2030- Product Image
Polycystic Kidney Disease Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Polycystic Kidney Disease Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674533
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The polycystic kidney disease drugs market is witnessing dynamic transformation as innovation, regulation, and patient-centric care converge to create evolving opportunities and challenges for senior decision-makers.

Market Snapshot: Polycystic Kidney Disease Drugs Market Overview

The global polycystic kidney disease drugs market grew from USD 539.54 million in 2024 to USD 563.92 million in 2025. With a projected CAGR of 4.63%, the market is expected to reach USD 708.01 million by 2030. This sustained growth reflects innovation in targeted therapies, evolving regulatory frameworks, and strong demand for effective disease management.

Scope & Segmentation

This report provides an in-depth examination of the polycystic kidney disease drugs market, analyzing core segments, regional markets, and breakthrough technologies advancing patient outcomes.

  • Drug Types: Angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, mTOR inhibitors, somatostatin analogs, vasopressin receptor antagonists.
  • Mode of Administration: Intravenous or injectable pharmaceuticals, oral medications.
  • Disease Types: Autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • End-Users: Clinics, homecare settings, hospitals.
  • Regional Markets: Americas (United States with key states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including major and emerging economies), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Players: Includes Apotex Inc., Boehringer Ingelheim GmbH, Centessa Pharmaceuticals Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Fresenius Kabi AG, Galapagos NV, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Viatris Inc.

Key Takeaways for Executive Strategy

  • Adoption of targeted molecular therapies and precision medicine is rapidly reshaping treatment paradigms and fueling competitive differentiation within the polycystic kidney disease drugs market.
  • Integration of biomarker-driven clinical trial designs and digital health technologies is accelerating approval timelines and supporting more efficient patient monitoring and adherence.
  • Public-private partnerships and cross-disciplinary collaborations are crucial in turning fundamental research into real-world clinical solutions, driving innovation across the drug development pipeline.
  • Value-based reimbursement models are influencing pricing strategies, requiring manufacturers to prioritize robust evidence of long-term clinical and economic outcomes.
  • Strengthening supply chain agility and engaging with regional distribution networks will be essential as hospitals, clinics, and homecare providers expand their roles in therapy delivery and patient management.
  • Emerging biotechnology firms are leveraging first-in-class mechanisms and agile iteration to become valuable partners for established pharmaceutical players seeking innovation.

Tariff Impact: Navigating the 2025 U.S. Tariff Adjustments

Impending 2025 U.S. tariff measures compel stakeholders to revisit sourcing and distribution strategies for polycystic kidney disease therapeutics. Domestic production initiatives are intensifying, yet key raw materials remain globally concentrated. Strategic actions, such as dual-sourcing and near-shoring, are critical for mitigating cost volatility and supply disruptions. Contract manufacturers and active pharmaceutical ingredient suppliers are vital in transitioning toward more resilient operations. Simultaneously, pricing and value positioning will require close collaboration with health economics experts to adapt to shifting reimbursement criteria. Overall, tariff adjustments represent a strategic inflection point, prompting both risk mitigation and opportunity capture across the market ecosystem.

Methodology & Data Sources

This report synthesizes rigorous secondary research with primary interviews and quantitative surveys. Academic literature, regulatory filings, and patent databases underpin foundational insights, validated and refined through direct engagement with industry and clinical experts. Triangulation ensures data integrity and analytical accuracy throughout.

Why This Report Matters

  • Enables leadership to make informed product portfolio and investment decisions by mapping market drivers, segment dynamics, and regional risk factors.
  • Delivers actionable intelligence on evolving regulatory requirements and payer expectations to support go-to-market and pricing strategies.
  • Equips stakeholders to identify strategic partnerships and innovation opportunities to optimize market access and sustain long-term competitive advantage.

Conclusion

The polycystic kidney disease drugs market offers significant growth opportunities for companies navigating complex regulatory, operational, and customer landscapes. Leveraging evidence-based strategy and systemic agility is key. Senior leaders who integrate market intelligence with robust execution will drive enduring value for their organizations and patients.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing use of gene editing approaches such as CRISPR to correct PKD1 and PKD2 mutations in preclinical studies
5.2. Rising clinical trials exploring combination therapy targeting mTOR and cAMP signaling pathways for ADPKD management
5.3. Growing integration of digital health platforms for remote monitoring of kidney function in PKD patients
5.4. Expansion of biomarker-based patient stratification methods to personalize treatment regimens for ADPKD
5.5. Regulatory agencies granting accelerated approval pathways for novel PKD therapies under orphan drug designations
5.6. Increased investment in small molecule modulators of polycystin protein trafficking to inhibit cyst growth
5.7. Emerging utilization of real-world evidence to support safety and efficacy of long-term tolvaptan therapy in ADPKD
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Polycystic Kidney Disease Drugs Market, by Drug Type
8.1. Introduction
8.2. Angiotensin II Receptor Blockers
8.3. Angiotensin-Converting Enzyme Inhibitors
8.4. Calcium Channel Blockers
8.5. mTOR Inhibitors
8.6. Somatostatin Analogs
8.7. Vasopressin Receptor Antagonists
9. Polycystic Kidney Disease Drugs Market, by Mode of Administration
9.1. Introduction
9.2. Intravenous (IV) or Injectable
9.3. Oral
10. Polycystic Kidney Disease Drugs Market, by Disease Type
10.1. Introduction
10.2. Autosomal Dominant Polycystic Kidney Disease
10.3. Autosomal Recessive Polycystic Kidney Disease
11. Polycystic Kidney Disease Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Polycystic Kidney Disease Drugs Market, by End-User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
13. Americas Polycystic Kidney Disease Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Polycystic Kidney Disease Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Apotex Inc.
16.3.2. Boehringer Ingelheim GmbH
16.3.3. Centessa Pharmaceuticals Limited
16.3.4. Eli Lilly and Company
16.3.5. F. Hoffmann-La Roche AG
16.3.6. Fresenius Kabi AG
16.3.7. Galapagos NV
16.3.8. Kyowa Hakko Kirin Co., Ltd.
16.3.9. Merck & Co., Inc.
16.3.10. Mitsubishi Tanabe Pharma Corporation
16.3.11. Novartis International AG
16.3.12. Otsuka Pharmaceutical Co., Ltd.
16.3.13. Pfizer Inc.
16.3.14. Sanofi S.A.
16.3.15. Teva Pharmaceutical Industries Ltd.
16.3.16. Vertex Pharmaceuticals Incorporated
16.3.17. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET: RESEARCHAI
FIGURE 26. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 75. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 76. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 77. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 80. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 81. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 84. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 85. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 86. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 87. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 90. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 91. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 94. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 100. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 110. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 111. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 132. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 136. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 137. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 138. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 139. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 142. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 143. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 146. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 147. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 148. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 149. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 152. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 153. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 156. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 162. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 163. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 166. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 167. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 168. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 169. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 172. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 173. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 176. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 177. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 178. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 179. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 182. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 183. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 186. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 202. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 206. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 212. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 216. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 217. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 218. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 219. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 222. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 223. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 226. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 231. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 232. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 233. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 236. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 237. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 238. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 239. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 242. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 243. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 246. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 247. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 248. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 249. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 252. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 253. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 256. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 262. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 263. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 266. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 272. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 273. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 276. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 277. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 278. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 279. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 282. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 283. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 286. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 287. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 288. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 289. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 292. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 293. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 296. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Polycystic Kidney Disease Drugs market report include:
  • Apotex Inc.
  • Boehringer Ingelheim GmbH
  • Centessa Pharmaceuticals Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Galapagos NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 563.92 Million
Forecasted Market Value ( USD ) by 2030 $ 708.01 Million
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Polycystic Kidney Disease Drugs Market Report and Forecast 2025-2034 - Product Image

Polycystic Kidney Disease Drugs Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Polycystic Kidney Disease Drug Pipeline Analysis Report 2025 - Product Image

Polycystic Kidney Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Polycystic Kidney Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Autosomal Dominant Polycystic Kidney Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Autosomal Dominant Polycystic Kidney Disease Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • 100 Pages
  • Global
From
Late Stage Chronic Kidney Disease Drugs Market Report 2025 - Product Image

Late Stage Chronic Kidney Disease Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Market

Polycystic Kidney Disease (PKD) is a genetic disorder that affects the kidneys and other organs. It is characterized by the growth of numerous cysts in the kidneys, which can lead to kidney failure. Treatment for PKD includes medications to reduce the size of the cysts, slow their growth, and reduce the risk of complications. The market for drugs to treat PKD is part of the larger market for drugs to treat liver and kidney disorders. These drugs are used to treat a variety of conditions, including PKD, chronic kidney disease, and liver cirrhosis. The market is driven by the increasing prevalence of these disorders, as well as advances in medical technology and the development of new drugs. Companies in the PKD drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.